Table of Contents Author Guidelines Submit a Manuscript
Tuberculosis Research and Treatment
Volume 2014, Article ID 626797, 6 pages
Research Article

Pharmacovigilance and Moroccan Tuberculosis Public Program: Current Situation

1Moroccan Anti Poison and Pharmacovigilance Center, Rabat 10000, Morocco
2Direction of Epidemiology and Lung Diseases of Morocco, Rabat 10000, Morocco
3University Hospital Moulay Youssef of Morocco, Rabat 10000, Morocco
4Laboratory of Genetics and Biometry, University Ibn Tofail, Kenitra 14000, Morocco

Received 26 February 2014; Accepted 25 May 2014; Published 12 June 2014

Academic Editor: Jacques Grosset

Copyright © 2014 Driss Soussi Tanani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The objective of this work is to demonstrate the interest of integration of pharmacovigilance in Moroccan Tuberculosis Control Program (MTCP). Design and Data Collection. The integration of pharmacovigilance in MTCP was conducted in October 2012 with the Global Fund support. We compared the reports notified before and after this integration (period 1: January 2010–October 2012; period 2: October 2012–December 2013). The detection of signals was based on the Information Component available in VigiMine. We used the SPSS version 10.0 and MedCalc version 7.3 for data analysis. Results. The average number of spontaneous reports increased from 3.6 to 37.4 cases/month (). The average age was years; the sex ratio was 0.8. Hepatic reactions (32.7%) predominated during the first period, while skin reactions (24.1%) were in the second period (), and 40.9% of cases in the first period were serious against 15.8% in second period (). Nine signals were generated (hepatic enzyme increase, cholestasis, jaundice, arthralgia, acne, lower limb edema, pruritus, skin rashes, and vomiting). Conclusion. The integration of pharmacovigilance in Moroccan Tuberculosis Control Program improved the management of ADRs and detected new signals of antituberculosis drugs.